Independent education resourceInformation here does not replace care from a qualified health professional.
Peptide Therapy GuideClear peptide education

Educational guide

Protein Identified That May Decrease Radiation Side-Effects

Researchers at the University of Colorado Boulder published a study (“Cysteine Protease Cathepsin B Mediates Radiation-Induced Bystander Effects”) in Nature that sheds new light on the precise mechanism behind the radiation-induced bystander effect (RIBE). The

Written by Peptide Therapy Guide Editorial Team
For education only

This guide cannot diagnose a condition or recommend a personal treatment plan. Discuss medical questions with a qualified professional.

Researchers at the University of Colorado Boulder published a study (“Cysteine Protease Cathepsin B Mediates Radiation-Induced Bystander Effects”) in Nature that sheds new light on the precise mechanism behind the radiation-induced bystander effect (RIBE). The team identified both a protein released by irradiated cells and the pathway it takes to influence healthy ones. Ultimately, researchers hope it could lead to a medication patients could take before radiation treatment.

RIBE is a phenomenon in which irradiated cells leak chemical signals that can travel some distance to damage unexposed healthy cells. Many patients suffer side effects, such as hair loss, fatigue, and skin problems. This bystander effect may also make targeted cells resistant to radiation treatment.

“Although RIBEs have important implications for radioprotection, radiation safety and radiotherapy, the molecular identities of RIBE factors and their mechanisms of action remain poorly understood. Here we use Caenorhabditis elegans as a model in which to study RIBEs, and identify the cysteine protease CPR-4, a homologue of human cathepsin B, as the first RIBE factor in nematodes, to our knowledge,” write the investigators. “Our study provides crucial insights into RIBEs, and will facilitate the identification of additional RIBE factors and their mechanisms of action.”

“Inhibiting RIBE would allow doctors to kill two birds with one stone,” said lead author Ding Xue, Ph.D., a professor of molecular, cellular, and developmental biology at CU Boulder who collaborated with colleagues in China, Taiwan, and Japan for the study. “We could minimize the bad effects of radiotherapy on healthy bystander cells, and at the same time, enhance cancer cell killing by radiotherapy.”

To be sure RIBE occurred in C. elegans, researchers exposed a population of the worms to radiation, then took a medium secreted by the C. elegans cells and bathed healthy C. elegans in it. The once-healthy animals began to show increased embryo deaths and other signs of RIBE.

The researchers then systematically treated the medium with agents designed to destroy proteins, DNA, and RNA, in order to determine which might be a key compound at play in RIBE. When the medium was treated with a protease, C. elegans exposed to it did not show signs of RIBE.

Once the scientists discovered that the agent causing RIBE was a protein, they used mass spectrometry to establish which proteins present in the medium were at play. CPR-4 emerged as the prime candidate, and cathepsin B is known to be a biomarker in several types of cancer.

Next the group studied which biological pathway enabled CPR-4 to signal changes in healthy cells that were never exposed to radiation. They identified a pathway mediated by the insulin-like growth factor receptor DAF-2. To confirm these findings, they irradiated the heads of C. elegans who either lacked the gene that codes for CPR-4 or lacked the gene that codes for the insulin-like growth factor receptor DAF-2. The bystander effect was blunted, with cells elsewhere in the body remaining healthy.

The study also found that tumor suppressor gene P53 may be at play in RIBE, prompting cells to produce more of the damaging CPR-4 protein when a cell is exposed to radiation.

“This is basically the first comprehensive study to identify the factor and mechanisms behind this radiation-induced bystander effect in animals,” said Dr. Xue, who hopes to work with other researchers in the future to identify other RIBE factors and mechanisms and help develop drugs that inhibit them.

Connected reading

Helpful context for this guide

Source-derived material selected through this article’s indexed topics.

Related questions

01How stable is the antibody?

A crucial question often addressed during preclinical development focuses on the in vivo stability of therapeutic antibodies. Increasing the half-life of a therapeutic antibody has several benefits ranging from higher treatment efficacy to increased advantages for the patients who will have a fewer number of therapy sessions and a reduced cost. Given these compelling benefits, following the identification of therapeutic antibodies with the desired specificity, developers usually subject them to a refinement step to increase their stability. This process is often hindered by the lack of reliable experimental tools to predict the half-life of antibodies in patients. The major hurdle of using mouse models to predict antibody stability in the serum lies in the way immunoglobulin proteins are processed by the organism. In mammals, most proteins circulating in the serum undergo constant uptake by endothelial cells and are routed through the endosomes to the lysosomal compartment for degradation. In the endosomes, immunoglobulin G (IgG) proteins are recognized and bound by a transmembrane protein, called the neonatal Fc receptor (FcRn), which mediates their recycling to the plasma membrane and subsequent release back into the serum. As a result, the half-life of IgGs are significantly extended by this mechanism. Since most therapeutic antibodies belong to the IgG class, this recycling system is very relevant for their relative stability in the body. Remarkably, the relative affinity between IgGs and FcRn is extremely disparate between different species, with the mouse receptor showing a much higher affinity than its human counterpart.

Source: www.genengnews.com ↗
02Undruggable or unscreenable?

Another obstacle to discovering new PPI inhibitors is the lack of libraries designed to hunt for them, points out Philippe Roche, PhD, senior scientist at the Integrative Structural and Chemical Biology team at the Cancer Research Center of Marseilles, France. “If you screen PPIs using libraries that were designed for kinases or GPCRs, that’s why you don’t get a lot of good results,” he says. To that end, his group began assembling a library focused on orthosteric inhibitors of PPIs. The result was 2P2Idb, a hand-curated, structural database cataloguing orthosteric inhibitors of PPIs for which the interface had been 3D characterized. From analyzing these known PPI inhibitors, and what structures they had in common, Roche and his colleagues developed a model to predict whether compounds would likely inhibit PPIs. Using this method, 2P2Idb creates an enriched screening library that dramatically increases the hit rate compared to standard libraries. Having proven their success with a small library of 1600 compounds, they are in the process of expanding the library to 10,000 compounds. Once that’s published, “the idea is to make this library available to labs around the world,” Roche says. “We will provide the library free of charge for people to be able to screen PPI targets.”

Source: www.genengnews.com ↗
P

About the author

Peptide Therapy Guide Editorial Team

Editorial team for Peptide Therapy Guide.

View all articles →